Suppression of AGO2 by miR-132 as a determinant of miRNA-mediated silencing in human primary endothelial cells  by Leonov, German et al.
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The  abundance  of  miR-132  ranges  from  constitutively  high  in the  brain  where it is  necessary  for  neu-
ronal  development  and function,  to inducible  expression  in haematopoietic  and  endothelial  cells  where
it  controls  angiogenesis  and immune  activation.  We  show  that expression  of  AGO2,  a protein  central  to
miRNA-mediated  gene  silencing  and  miRNA  biogenesis,  is  negatively  regulated  by  miR-132.  Using HeLa
cells,  we  demonstrate  that  miR-132  interacts  with  the AGO2  mRNA  3′UTR  and  suppresses  AGO2  expres-
sion  and  AGO2-dependent  small  RNA-mediated  silencing.  Similarly,  miR-132  over-expression  leads  to
AGO2  suppression  in primary  human  dermal  lymphatic  endothelial  cells  (HDLECs).  During  phorbol  myris-
tate  acetate  (PMA)-activation  of HDLECs,  miR-132  is induced  in  a CREB-dependent  manner  and  inhibitionNA-binding proteins
GO2
iR-132
of  miR-132  results  in  increased  AGO2  expression.  In agreement  with  the  role  of AGO2  in maintenance
of  miRNA  expression,  AGO2  suppression  by miR-132  affects the  steady  state  levels  of  miR-221  and  miR-
146a,  two miRNAs  involved  in angiogenesis  and  inﬂammation,  respectively.  Our  data  demonstrate  that
the  miRNA-silencing  machinery  is subject  to autoregulation  during  primary  cell  activation  through  direct
suppression  of  AGO2  by  miR-132.
© 2015  The  Authors.  Published  by  Elsevier  Ltd.  This  is  an  open  access  article  under the  CC  BY license. Introduction
The mature miR-132 (miR-132-3p) is derived from the pri-
ary miR-132/miR-212 cluster, found in the intergenic region of
hromosome 17p13.3. miR-132 and miR-212 have the same seed
equence and potential targets, although miR-132 is the prefer-
ntially expressed miRNA from the cluster (Lagos et al., 2010).
he transcription of miR-132/miR-212 cluster is dependent on
AMP response element-binding (CREB) protein phosphorylation
Vo et al., 2005), which is inducible in an ERK-1/2 and MSK-1/2
ependent manner (Remenyi et al., 2010). miR-132 has been impli-
ated in neuronal function and development (Remenyi et al., 2010;
ayman et al., 2008), circadian rhythm control (Alvarez-Saavedra
t al., 2011), angiogenesis (Anand et al., 2010), and regulation of
nnate immune responses (Lagos et al., 2010; Shaked et al., 2009). In
ndothelial cells, upregulation of miR-132 positively controls pro-
iferation, angiogenesis and tumour growth in response to vascular
ndothelial growth factor A (VEGF-A) by suppressing p120RasGap
∗ Corresponding author.
E-mail address: dimitris.lagos@york.ac.uk (D. Lagos).
ttp://dx.doi.org/10.1016/j.biocel.2015.10.006
357-2725/© 2015 The Authors. Published by Elsevier Ltd. This is an open access article u(http://creativecommons.org/licenses/by/4.0/).
(RASA1) (Anand et al., 2010). During viral infection of human cells
in vitro, miR-132 acts as a negative regulator of inﬂammation in
endothelial cells and macrophages by modulating EP300 (Lagos
et al., 2010). Interestingly, EP300 is a co-transcriptional activator
that is required for miR-132 expression, which may  contribute to
the transient expression of this miRNA, as seen in endothelial cells.
Although the expression of miR-132 is low under basal conditions
in HDLECs (approximately 50–100 copies per cell), endothelial
activation leads to an early upregulation of miR-132 required for
endothelial cell proliferation and angiogenesis (Anand et al., 2010;
Lagos et al., 2010).
The abundance of mature miRNAs can be regulated at multiple
steps of miRNA biogenesis by altering the expression or function
of miRNA machinery proteins. The knock-down of DICER (Zhang
et al., 2012; Schmitter et al., 2006) or AGO2 (Schmitter et al., 2006)
has been correlated with a global drop of mature miRNA expres-
sion levels. DICER (Bernstein et al., 2003) and AGO2 (Morita et al.,
2007) knock-out mice are embryonic lethal and this demonstrates
the importance of miRNA-mediated regulation of gene expression
during the early stages of embryo development. Reversely, the
upregulation of AGO2 has been associated with a global increased
expression of miRNAs (Martinez and Gregory, 2013; Winter and
nder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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tig. 1. miR-132 interacts with AGO2 3′UTR. (A) mRNA levels of RBPs following lentivi
average mRNA levels from two independent screens shown). (B) Conservation of
GO2  3′UTR).
iederichs, 2011). Global changes in miRNA expression levels lead
o disruptions in cellular function, such as poor neovascularisa-
ion and vascular deformation reported in DICER knock-out mice
Bernstein et al., 2003).
The very nature of miRNA-mediated gene regulation means that
he formation of negative feedback regulatory loops can occur,rexpression of miR-132 and miR-132 mutant (M)  in HDLECs, 48 h post-transduction
 3′UTR region targeted by miR-132 (bold font – ‘seed’ site of miR-132 binding on
where a miRNA can be involved in regulating its own biogene-
sis by targeting components required for its speciﬁc transcription,
post-transcriptional processing, stability, or target accessibility.
In the context of miRNA biogenesis, such regulatory loops have
been identiﬁed in the regulation of DICER by let-7 in mammalian
cell lines (Tokumaru et al., 2008), AGO1 regulation by miR-168
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tems) for GAPDH (forward: 5′-GGAGTCAACGGATTTGGTCGTA-
3′; reverse: 5′-GGCAACAATATCCACTTTACCAGAGT-3′) and pri-
miR-126 (forward: 5′-TATCAGCCAAGAAGGCAGAA-3′, reverse:
Fig. 2. miR-132 over-expression suppresses AGO2 expression in HeLas. (A) Rela-G. Leonov et al. / The International Journal
n plants (Martínez de Alba et al., 2011), and ALG-1 regulation
y let-7 in Caenorhabditis elegans (Zisoulis et al., 2012). The reg-
lation of mammalian AGO2 by miR-184 has also been reported
uring cytokine stimulation (Roberts et al., 2013), and reported in
esponse to insulin stimulation and thereby controlling cell prolif-
ration (Tattikota et al., 2014). Of note, AGO2 is the only catalytically
ctive mammalian Argonaute family protein (Meister et al., 2004),
aking it essential for mRNA cleavage and effective in both siRNA
nd miRNA-mediated silencing.
Here, we identify an autoregulatory feedback mechanism that
nvolves AGO2 suppression by miR-132. We  have examined this
echanism in both transformed cell lines and activated primary
uman dermal lymphatic endothelial cells (HDLECs). We  demon-
trate that changes in AGO2 expression affect expression of speciﬁc
DLEC miRNAs, such as miR-221 and miR-146a, which have impor-
ant and critical roles in angiogenesis and inﬂammation (Li et al.,
009; Poliseno et al., 2006; Taganov et al., 2006; Yang et al., 2012).
verall, our ﬁndings reveal a novel mechanism regulating AGO2
xpression and provide mechanistic insight into the function of
iR-132 in human primary endothelial cells.
. Methods
.1. Cell culture
Human dermal lymphatic endothelial cells (HDLEC) were pur-
hased from Promocell and grown in endothelial cell growth
edium (Promocell) supplemented with 10 ng/mL VEGF-C (R&D).
ll HDLEC experiments were performed at passage 5. HDLECs
passage 5) fully maintain their proliferative capacity and differen-
iation markers (Hansen et al., 2010; Lagos et al., 2010), including
YVE1 (Supplementary Fig. 1). HeLa cells were grown in Dulbecco’s
odiﬁed eagle medium (DMEM) containing 10% FCS.
.2. Transfections with miRNA mimics and inhibitors, and RNA
nhibitors
Cells were transfected in 6-well plates in Opti-MEM using Oligo-
ectamine (Invitrogen) transfection reagent 18 h after seeding. The
iRNAs (OnTargetPlus SmartPool from Thermo Scientiﬁc), miRNA
imics (miRIDIAN from Thermo Scientiﬁc) were prepared at 25 nM
oncentration and Locked Nucleic Acid (LNA)-inhibitors of miR-
32 (Exiqon) were prepared at 50 nM concentration. Cells were
arvested 48 h post transfection.
.3. Lentiviral transduction
The miR-132/miR-212 cluster or AGO2-UTR were ampliﬁed
rom genomic DNA or cDNA respectively and subcloned into
he pSIN lentiviral vector using the NotI and BamHI restriction
nzymes. For lentiviral transduction, virions were produced as
escribed in (Lagos et al., 2008). HDLECs were infected for 48 h
efore harvesting.
.4. PMA  treatment
HDLECs were activated with PMA  for 24 h before harvesting.
MA  treatments were carried out 18 h after seeding cells into 6-well
lates, 48 h after miRNA inhibition, mimics transfection or siRNA
ransfection, and 30 h after lentiviral transduction.
.5. RNA preparation and qRT-PCRTotal RNA was extracted using the miRNEasy kit (Qiagen).
evels of mRNA were quantiﬁed by qRT-PCR using the Taq-
an  Universal PCR Master Mix  (Applied Biosystems) for AGO2chemistry & Cell Biology 69 (2015) 75–84 77
and pri-miR-132 (TaqMan primers from Applied Biosystems)
and using the SYBR Green Master Mix (Applied Biosys-tive Renilla luciferase (Rluc) activity for AGO2 WT  3′UTR, AGO2 Mutant 3′UTR and
EP300 WT 3′UTR, normalised to the average Rluc activity of each individual repli-
cate experiment in HeLas. (B) Expression of AGO1 and AGO2 protein in HeLas, 48 h
post-transfection with miR-132 mimics. (C) Levels of AGO2 mRNA in HeLas, 48 h
post-transfection with miR-132 mimics. *** Indicates p < 0.001.
7  of Bio
5
c
m
a
2
S
S
1
1
m
w
y
i
2
a
X
t
3
w
w
o
a
F
i
H
p8 G. Leonov et al. / The International Journal
′-CGTGGCGTCTTCCAGAAT-3′). Primers were used at 300 nM ﬁnal
oncentration. GAPDH was used as a loading control for AGO2, pri-
iR-126 and pri-miR-132. RNU6 was used as a loading control for
ll mature miRNAs (Applied Biosystems).
.6. Immunoblots and antibodies
Primary antibodies were prepared at 1:1000 for AGO1 (Cell
ignalling, D84G10), AGO2 (Cell Signalling, C34C6), CREB (Cell
ignalling, 48H2), phospho-CREB at Ser133 (Cell Signalling, 87G3),
:500 for EP300 (Abcam, 3G230), RASA1 (Santa Cruz, B4F8), and
:5000 for -actin (Cell Signalling, AC-15). Secondary goat anti-
ouse (Dako, P0447) and goat anti-rabbit (Dako, P0448) antibodies
ere prepared at 1:5000 conjugated to HRP. Western blot anal-
sis was carried out using ImageJ software for quantifying band
ntensities.
.7. Luciferase reporter assay
AGO2 3′UTR and EP300 3′UTR were ampliﬁed from HDLEC cDNA
nd subcloned into the psiCheck2 vector (Promega) using NotI and
hoI enzymes. Mutations were introduced at the AGO2 3′UTR at
he miR-132 binding site (WT: 5′-GUACAAUCCUUUUUCACUGUUU-
′; Mut: 5′-GUACAAUCCUUUUUCACUAAAU-3′). Luciferase assays
ere performed in HeLa cells. AGO2 and EP300 UTR constructs
ere transfected for 24 h after the 24 h miR-132 mimics (20 nM)
r NTC transfection. Relative light units (RLU) were measured with
 Fluoroscan Ascent FL luminometer (Thermo Scientiﬁc).
ig. 3. miR-132 over-expression suppresses AGO2 expression in HDLECs. (A) Expression
n  HDLECs, 48 h post-transduction. (B) Expression of AGO2, RASA1, EP300 protein in H
DLECs, 48 h post-transfection with miR-132 mimics. *** Indicates p < 0.001. (D) Expressi
ost-transfection. (E) AGO2 protein expression of two  experiments with a 24 h lentiviral chemistry & Cell Biology 69 (2015) 75–84
2.8. Let-7 silencing reporter assay
The let-7 silencing reporter assay was  carried out in HeLa cells
as previously described by (James et al., 2010) in the presence
of NTC/miR-132 mimics (20 nM)  or siNTC/siAGO2 (20 nM). The
luciferase reporter used (40 nM)  contained either a single fully com-
plementary site (si) or a seven times repeat of a mismatched site
(mi7) for let-7 binding.
2.9. Statistical analysis
Experimental results are presented as mean ± S.E. (error bars)
and were performed in 3 independent replicates unless other-
wise stated in the ﬁgure legend. Where appropriate, a two-tailed
unpaired Student’s t-test was  used to calculate the signiﬁcance of
the difference between treatments.
3. Results
3.1. miR-132 interacts with the AGO2 3′UTR
Gene ontology analysis of predicted miR-132 targets, using the
EIMMO  prediction analysis tool (Hausser et al., 2009), indicated
that RNA-binding proteins (RBPs) were over-represented amongst
miR-132 predicted targets (Supplementary Table 1). We utilised a
lentiviral construct containing the miR-132/miR-212 locus (Lagos
et al., 2010) to screen for the effect of miR-132 on mRNA levels of 13
RBPs that were predicted miR-132 targets by multiple algorithms
 of AGO2 protein following lentiviral overexpression of miR-132 and miR-132 M
DLECs, 48 h post-transfection with miR-132 mimics. (C) mRNA levels of AGO2 in
on of AGO2 and RASA1 protein after a titration of miR-132 mimics in HDLECs, 48 h
overexpression of AGO2−UTR following a miR-132 overexpression in HDLECs.
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Supplementary Table 2). Over-expression of miR-132 and miR-212
n HDLECs resulted in a drop in AGO2 mRNA (Fig. 1A). The effect was
bolished when using a construct where the seed sequence of both
iR-132 and miR-212 is mutated (Fig. 1A).
We identiﬁed a potential miR-132 binding site in the AGO2
′UTR. The binding site is conserved across mammalian species
ith the exception of Sorex araneus (Fig. 1B). Based on this, we
urther investigated whether miR-132 interacted with the AGO2
′UTR region. The introduction of miR-132 mimic into HeLa cells
ed to a drop in luciferase signal for a reporter containing the AGO2
′UTR (Fig. 2A), compared to the non-targeting control (NTC). A
riple consecutive base pair mutation introduced at the start of the
eed site of the miR-132 binding in the AGO2 3′UTR reversed the
uppression of luciferase activity by miR-132 mimic. The effect of
iR-132 on the AGO2 3′UTR was similar to that on the EP300 3′UTR,
 known miR-132 target (Lagos et al., 2010). We  should note that
ndogenous miR-132 expression in HeLa cells is at similarly low
evels to those observed in HDLEC.
.2. miR-132 over-expression suppresses AGO2 expression
Having shown that miR-132 can directly interact with the pre-
icted miR-132-binding site in the AGO2 3′UTR, we  studied the
ffect of miR-132 over-expression on AGO2 expression. Transfec-
ion of miR-132 synthetic mimics into HeLa cells resulted in a
ecrease in AGO2 protein and mRNA levels (Fig. 2B and C). Similarly,
n HDLECs the observed decrease in AGO2 mRNA levels following
ig. 4. Over-expression of miR-132 affects AGO2 function in HDLECs. (A) Let-7 silencing
mi7)  let-7 binding sites (16) in HeLas. (B) Effect of AGO2 knockdown on miR-16, miR-30
ost-transfection with siAGO2 (n = 2). (C) Levels of miR-126 and miR-221 in HDLECs, 48 h
o  primary miR-126 in HDLECs, 48 h post-transfection with miR-132 mimics. (E) miR-12
GO2−UTR following a miR-132 overexpression in HDLECs. * Indicates p < 0.05, ** indicatechemistry & Cell Biology 69 (2015) 75–84 79
over-expression of the miR-132/miR-212 cluster (Fig. 1A) corre-
lated with decreased AGO2 protein levels (Fig. 3A). Transfection
of synthetic miR-132 mimics into HDLECs suppressed AGO2 pro-
tein expression to the same extent as the known miR-132 targets
EP300 and RASA1 (Fig. 3B), and also resulted in a drop in AGO2
mRNA (Fig. 3C). The suppression of AGO2 in HDLECs was  miR-
132-dose-dependent with maximum suppression observed when
using 15–25 nM concentration (Fig. 3D; Supplementary Fig. 2). To
verify that the effect of miR-132 on AGO2 expression in HDLECs
was indeed through direct targeting of the AGO2 3′UTR region,
we utilised a lentiviral construct expressing FLAG-tagged AGO2
but lacking its 3′UTR region (AGO2−UTR). We  found that AGO2−UTR
expression in HDLECs was  not affected by miR-132 mimics (indi-
cated by anti-FLAG M2,  Fig. 3E). As expected, miR-132 mimics in
AGO2−UTR over-expressing HDLECs resulted in a drop in endoge-
nous AGO2, shown by a decrease in total AGO2 levels.
3.3. miR-132 over-expression affects AGO2 function
Next, we tested whether the observed level of AGO2 regu-
lation by miR-132 was functionally relevant. We  employed an
endogenous let-7a silencing reporter constructs containing a fully
complementary (si) or multiple copies of bulged (mi7) Let-7
binding sites downstream of a luciferase reporter as previously
described (James et al., 2010). The si reporter gives a read-out of
the RNAi function of AGO2, which relies on full complementarity
between the small RNA (in this case let-7a) and the target. The
 activity reporter assay with a fully complementary (si) and multiple mismatched
c, miR-126, miR-132, miR-139-5p, miR-146a and miR-221 levels in HDLECs, 48 h
 post-transfection with miR-132 mimics. D. Levels of primary miR-126 and mature
6 and miR-221 levels of two experiments with a 24 h lentiviral overexpression of
s p < 0.01, and *** indicates p < 0.001, n.s. not signiﬁcant.
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vig. 5. PMA  induces miR-132 expression by activating CREB. (A) Expression of ph
ature  and primary miR-132 in HDLECs, 6 h and 24 h post-PMA treatment (n = 4).
reated  with PMA  over a 48 h period.
i7  reporter provides a read-out of the miRNA silencing function
f Ago2 as it is not susceptible to cleavage by AGO2 endonucle-
se activity. We  observed that the introduction of miR-132 mimics
r siAGO2 resulted in derepression of both siRNA and miRNA
eporter constructs, as indicated by derepression of the Rluc activity
Fig. 4A). These ﬁndings show that miR-132-mediated regulation
f AGO2 is sufﬁcient to negatively impact AGO2 siRNA and miRNA-
ediated silencing functions, thus further deﬁning the importance
f this regulatory feedback mechanism.
To test the functional signiﬁcance of miR-132-mediated sup-
ression of AGO2 in HDLECs, we took advantage of the fact that
oss of AGO2 expression results in decreased miRNA expression
Schmitter et al., 2006; Morita et al., 2007). We  conﬁrmed that
his was the case in HDLECs by determining expression of several
iRNAs following siRNA mediated knockdown of AGO2 (Fig. 4B).
imilarly, miR-132-mediated AGO2 suppression resulted in down-
egulation of miR-126 and miR-221 (Fig. 4C). The decrease in
ature miR-126 levels was due to a reduction in the mature to
rimary miRNA ratio (Fig. 4D), suggesting that post-transcriptional
egulation of miR-126 contributes to the reduction in its levels in
iR-132-over-expressing HDLECs, being consistent with the effect
f miR-132 on AGO2 expression. This was further supported by
he fact that physiologically relevant over-expression of AGO2−UTR
n HDLECs transfected with control or miR-132 mimics partially
estored miR-126 and miR-221 expression. Over-expression of
iR-132 in HDLECs transduced with control lentivirus (pSIN)
esulted in statistically signiﬁcant down-regulation of miR-126 and
iR-221. In contrast, transfection of miR-132 mimics in HDLECs
ransduced with AGO2 lentivirus did not signiﬁcantly affect miR-
26 and miR-221 levels (Fig. 4E)..4. PMA  induces miR-132 expression in HDLECs
miR-132 expression is transcriptionally controlled by CREB acti-
ation (Lagos et al., 2010; Remenyi et al., 2010; Vo et al., 2005). We-CREB during PMA  activation (25 nM)  in HDLECs over a 24 h period. (B) Levels of
icates p < 0.01. (C) Time course of mature and primary miR-132 levels in HDLECs
used PMA, a potent activator of PKC that results in CREB phosphor-
ylation (Mao  et al., 2007). We  showed that CREB is phosphorylated
during the ﬁrst few hours post-PMA treatment and the effect is lost
after 24 h (Fig. 5A; Supplementary Fig. 3A). The activation of CREB
led to an induction of mature miR-132 expression over a range of
PMA  concentrations (Supplementary Fig. 3B). The most potent and
sustained induction of miR-132 was  obtained following treatment
with 25 nM PMA  and this concentration was used for all further
experiments.
The expression of primary and mature miR-132 was mea-
sured at 6 h and 24 h post-PMA treatment (Fig. 5B) and a more
detailed time-course of expression was performed over 48 h
(Fig. 5C). Consistent with CREB-mediated transcriptional activa-
tion, pri-miR-132 was  up regulated during the ﬁrst few hours
post-PMA treatment and returned to near-baseline expression
level by 24 h. However, mature miR-132 levels showed only a
modest decrease over the time-course following the initial induc-
tion, suggesting it was more stable than pri-miR-132 in these
conditions.
3.5. Inhibition of endogenous miR-132 leads to increased AGO2
expression
We  have previously shown that miR-132 expression in HDLECs
becomes functionally relevant only when induced (Lagos et al.,
2010). Therefore, we  exploited the PMA-inducible miR-132 expres-
sion in vitro system in HDLECs to determine the effect of
endogenous miR-132 on AGO2 expression. Inhibition of miR-132
induction (Fig. 6A) resulted in statistically signiﬁcant induction of
AGO2 expression in PMA-treated HDLECs (24 h), an effect that was
not observed in HDLECs transfected with control miRNA inhibitors
(Fig. 6B and C). PMA  treatment or miR-132 inhibition did not affect
AGO2 mRNA levels (Fig. 6D).
G. Leonov et al. / The International Journal of Biochemistry & Cell Biology 69 (2015) 75–84 81
Fig. 6. Inhibition of endogenous miR-132 leads to increased AGO2 expression. (A) Levels of miR-132 in HDLECs 24 h post-PMA treatment following miR-132 inhibition.
(B)  AGO2 protein expression in HDLECs 24 h post-PMA treatment following miR-132 inhibition. (C) Quantiﬁcation of AGO2 protein expression 24 h post-PMA treatment
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f  AGO2 mRNA 24 h post-PMA treatment following miR-132 inhibition in HDLECs (
As the changes in AGO2 expression following PMA  treatment
nd miR-132 inhibition were modest, we tested whether such
ffects could affect AGO2 function. We over-expressed AGO2−UTR
uring PMA-activation of HDLECs to a similar level (Fig. 7A) as
bserved during miR-132 inhibition. This level of over-expression
f AGO2−UTR in HDLECs resulted in a modest increase in expres-
ion of miR-126, miR-132, miR-146a, and miR-221, the effect
eing more prominent for the latter two miRNAs (Fig. 7B).
iR-221 was down-regulated and miR-146a up-regulated during
MA-activation (Fig. 7C). In agreement with these ﬁndings and the
ffect of miR-132 on AGO2 expression (Fig. 6B), we  observed an
ncrease in miR-221 and miR-146a expression in response to miR-
32 inhibition in PMA-activated HDLECs (Fig. 7D), while miR-126
xpression was unaffected. Overall, these results further supported
hat endogenous miR-132 can regulate AGO2 expression in acti-
ated HDLECs.ch individual experiment (n = 4). * Indicates p < 0.05, n.s. not signiﬁcant. (D) Levels
4. Discussion
Here we  demonstrate that miR-132 can suppress expression of
AGO2 through a canonical miRNA-mediated silencing mechanism,
and that this interaction ﬁne-tunes AGO2 expression in activated
primary endothelial cells. Our ﬁndings indicate that steady state
expression of some miRNAs is highly sensitive to changes in
AGO2 expression in HDLECs. This is in agreement with previous
reports demonstrating that loss of AGO2 has variable effects on
steady-state levels of individual miRNAs (Diederichs and Haber,
2007; Winter and Diederichs, 2011; Bronevetsky et al., 2013).
Importantly, we  ﬁnd that miR-132 is involved in modulating the
availability of AGO2 to perform its function in siRNA and miRNA-
mediated silencing and in stabilising miRNA expression (Winter
and Diederichs, 2011). This provides support for a model accord-
ing to which post-transcriptional regulation of miR-132 by AGO2
82 G. Leonov et al. / The International Journal of Biochemistry & Cell Biology 69 (2015) 75–84
Fig. 7. Regulation of AGO2 affects miRNA abundance. (A) AGO2 protein expression in HDLECs 24 h post-PMA treatment following a 30 h AGO2−UTR lentiviral overexpression.
(B)  miR-126, miR-132, miR-146a and miR-221 levels in HDLECs 48 h post-AGO2−UTR lentiviral overexpression. (C) miR-126, miR-132, miR-146a and miR-221 levels in
HDLECs  24 h post-PMA treatment. (D) miR-126, miR-146a and miR-221 levels 48 h post-miR-132 LNA inhibition in PMA  activated HDLECs. (E) Schematic diagram depicting
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eMA/miR-132/AGO2-associated regulatory loops: AGO2 regulation by a (1) negativ
eed  forward loop (miR-146a).
s coupled to miR-132 mediated regulation of AGO2, maintaining
ptimal miR-132 and AGO2 expression during haematopoietic or
ndothelial cell activation. Although basal miR-132 expression is
ow in non-neuronal cells, during cellular activation its expres-
ion increases to functionally relevant levels as demonstrated by
ts role in modulating the innate immune response (Lagos et al.,
010) and angiogenesis (Anand et al., 2010). Of note, miR-132 has
een previously shown to participate in similar negative feedback
oops maintaining homeostatic levels of EP300 in endothelial and
mmune cells (Lagos et al., 2010) and MeCP2 expression in neu-
ons, where the baseline expression of miR-132 is higher but also
nducible (Klein et al., 2007). We  speculate that the propensity of
iR-132 to form negative feedback loops with its mRNA targets is
ssential for its activity-dependent expression and function bothback loop (miR-132), (2) coherent feed forward loop (miR-221), and (3) incoherent
outside and within the brain. Our ﬁndings indicate that in PMA-
treated HDLECs mature miR-132 is substantially longer-lived than
its primary transcript, which might provide one possible explana-
tion for the need for multiple negative feedback loops controlling
miR-132 expression and function.
In our study, we  focussed on endothelial cells as miR-132 has
been shown to regulate angiogenic and inﬂammatory responses in
these cells. For the same reason, when looking for functional con-
sequences of AGO2 regulation we  chose to measure expression of
miRNAs that have previously been reported to be involved in angio-
genesis or inﬂammation. For example, miR-221 (Poliseno et al.,
2006; Li et al., 2009) is known as an anti-angiogenic miRNA, miR-
126 is essential for endothelial cell survival (Sun et al., 2010; Wang
et al., 2008), and miR-146a involved in inﬂammatory responses in
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ndothelial cells (Lagos et al., 2010). We  show that treatment of
DLECs with PMA results in an induction of the pro-angiogenic
iR-132, and a decrease in the anti-angiogenic miR-221 expres-
ion, in agreement with the previously reported pro-angiogenic
ctivity of PMA  (Montesano and Orci, 1985). Interestingly, during
ndothelial cell activation, minimal over-expression of AGO2 or
nhibition of miR-132 result in increased miR-221 and miR-146a
xpression, in agreement with the proposed miR-132-mediated
GO2 regulation. We  should note that the magnitude of the effect
f miR-132 inhibition on miR-221 and miR-146a indicates that
ther factors also contribute to the regulation of these miRNAs
n activated HDLECs. However, our results suggest that regula-
ion of AGO2 due to miR-132 induction is a failsafe mechanism
hat ensures maintained suppression of miR-221, and limits the
xtent of the anti-inﬂammatory activity miR-146a (Fig. 7E). Indeed,
iRNAs are often components of such coherent (e.g. miR-221) or
ncoherent (e.g. miR-146a) feed forward loops (Herranz and Cohen,
010). It would be interesting to further investigate the relevance
f this intricate miRNA network in in vivo models of angiogenesis
nd in cells with high basal miR-132 expression, such as neurons.
Validated miR-132 targets are involved in chromatin modiﬁca-
ions (e.g. MeCP2, EP300, Jarid1a, SIRT1) (Alvarez-Saavedra et al.,
011; Yamakuchi, 2012) transcription (e.g. EP300) (Hasan et al.,
001), and mRNA splicing (e.g. PTBP2) (Smith et al., 2011), indicat-
ng a functional clustering of miR-132 targets around modulators
f the lifecycle of a mammalian mRNA. We  substantially expand
his concept to cover mRNA silencing, by revealing that miR-
32 can suppress AGO2. The major implication of these ﬁndings
s that a miR-132 can potentially act as a concurrent regulator
f transcription, splicing, and silencing in the cell. Deﬁning how
hese fundamental processes communicate is of paramount impor-
ance and particularly relevant to cellular stress responses, which
re characterised by highly dynamic, and accurate gene expres-
ion programmes. We  propose that the potential of miR-132 in
oordinating multiple molecular processes that determine gene
xpression can provide crucial clues towards understanding the
omplex and context-speciﬁc role of this miRNA in neurons and
aematopoietic and vascular cells.
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